Hemant Surgical Industries Limited has announced the execution of a strategic Semi Knocked Down (SKD) Manufacturing Agreement with Sonomed Escalon, USA, marking a significant step in the company's expansion into ophthalmic diagnostic device manufacturing. The agreement was disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agreement Overview

The partnership with Sonomed Escalon, a global leader in ophthalmic diagnostic imaging, focuses on the manufacturing of ophthalmic ultrasound diagnostic devices. The agreement encompasses both SKD manufacturing and plans for further localization to achieve 100% manufacturing capabilities in India.

Commercial Terms and Structure

Under the SKD Manufacturing Agreement, both parties have defined their scope of work for SKD operations and subsequent localization efforts. Sonomed Escalon has agreed to supply components in SKD form at preferential transfer pricing, providing cost advantages for the manufacturing process.

The pricing structure excludes several cost components:

• Taxes, duties, and customs charges
• Statutory levies
• Shipping costs (unless otherwise agreed)

Regulatory Compliance and Disclosures

The company confirmed that this transaction does not fall under related party transactions, despite the fact that the promoter was previously an authorized distributor of Sonomed Escalon. The agreement does not involve any shareholding arrangements between the parties, and no special rights such as director appointments or share subscription rights are included.

Strategic Implications

This manufacturing agreement represents Hemant Surgical Industries' strategic move to expand its capabilities in the ophthalmic diagnostic equipment sector. The partnership with an established global leader like Sonomed Escalon provides access to advanced technology and manufacturing expertise in specialized medical devices.

The phased approach from SKD manufacturing to complete localization aligns with India's manufacturing initiatives and could position the company as a significant player in the domestic ophthalmic diagnostic device market. The preferential pricing structure from Sonomed Escalon enhances the commercial viability of this manufacturing venture.

Hemant Surgical Industries Limited has announced receipt of a major purchase order worth ₹264.33 crores from the Central Medical Service Society (CMSS), Ministry of Health and Family Welfare, Government of India. The company disclosed this development through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Order Details and Specifications

The purchase order encompasses supply of sophisticated medical equipment including Flat Panel Detectors with two batteries and router, Hard Travel Case, and X-Ray Generators along with other utilities. The order value of ₹264.33 crores is inclusive of all taxes and duties, representing a significant business win for the medical equipment manufacturer.

Implementation Strategy

Despite final commercial terms and delivery schedules still being under discussion and finalization, Hemant Surgical Industries has agreed to commence supplies on an interim basis. This decision reflects the company's recognition of the national importance of the project and response to the specific request made by CMSS.

The order will be executed in tranches by September 30, 2026, subject to ongoing negotiations, terms, and any extensions that may be requested by the company to CMSS. This phased approach allows for systematic delivery while accommodating the finalization of remaining commercial terms.

Regulatory Compliance and Transparency

The company has confirmed that this order represents a domestic transaction with no related party implications. The promoter, promoter group, or group companies have no interest in the awarding entity, ensuring arm's length transaction principles are maintained.

Hemant Surgical Industries has committed to providing updates on the final commercial terms once they are concluded, maintaining transparency with stakeholders throughout the process. This substantial order reinforces the company's position in the medical equipment sector and its capability to serve critical healthcare infrastructure needs.